Irvine, CANCT07586202Now EnrollingIRB Ready

Carcinoma, Non-Small-Cell Lung Clinical Trial in Irvine, CA

Access cutting-edge carcinoma, non-small-cell lung treatment through this phase 2 clinical trial at a research site in Irvine. Study-provided care at no cost to qualified participants.

Sponsored by Janssen Research & Development, LLC

Quick Self-Assessment

See if you qualify for this Irvine location

Preparing your pre-screening questions…

Expert Care in Irvine

Access carcinoma, non-small-cell lung specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related carcinoma, non-small-cell lung treatment provided free

Apply for This Irvine Location

Check if you qualify for this carcinoma, non-small-cell lung clinical trial in Irvine, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Irvine

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Irvine site if eligible
  4. 4Begin participation

About This Carcinoma, Non-Small-Cell Lung Study in Irvine

The purpose of this study is to assess the ability to slow down or stop the growth of cancer with amivantamab combined with either lazertinib or chemotherapy (carboplatin and pemetrexed) in participants with resectable, epidermal growth factor receptor (EGFR) mutated, Stage II-IIIB non-small cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer. NSCLC may occur due to mutations (changes) in many genes, including EGFR.

Sponsor: Janssen Research & Development, LLC

Who Can Participate

Inclusion Criteria

Participant must have histologically or cytologically confirmed non-squamous non-small cell lung cancer (NSCLC) with completely resectable Stage II-IIIB N2 disease
Complete surgical resection of the primary NSCLC must be deemed achievable, as assessed by a multidisciplinary team evaluation
Participant must consent to a screening biopsy, if clinically feasible, if no adequate tumor tissue is available for a baseline sample
Participant may have a prior or concurrent second malignancy (other than the disease under study) which natural history or treatment is unlikely to interfere with any study endpoints of safety or the efficacy of the study treatment(s). Prior or concurrent second malignancies must be reviewed and agreed to with the medical monitor
Have an eastern cooperative oncology group (ECOG) performance status of 0 or 1

Exclusion Criteria

History of uncontrolled illness
Medical history of (non-infectious) interstitial lung disease (ILD)/pneumonitis, or has current interstitial lung disease (ILD)/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening
Suspected or known allergies, hypersensitivity, or intolerance to excipients of: the combination of amivantamab and lazertinib or carboplatin and pemetrexed
Presence of primary driver mutations (anaplastic lymphoma kinase \[ALK\], mesenchymal-epithelial transition \[MET\], human epidermal growth factor receptor 2 \[HER2\], proto-oncogene tyrosine-protein kinase ROS \[ROS1\], neurotrophic tyrosine receptor kinase \[NTRK\], B-Raf proto-oncogene \[BRAF\], REarranged during transfection \[RET\], or kirsten rat sarcoma viral oncogene homolog \[KRAS\]) , besides EGFR Exon 19del or Exon 21 L858R mutations, as determined by local genomic testing
Prior treatment with any systemic anti-cancer therapy for NSCLC including EGFR-tyrosine kinase inhibitor (TKI) therapy, chemotherapy, biologic therapy, immunotherapy, or any investigational drug

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Irvine?

Yes, this clinical trial (NCT07586202) has an active research site in Irvine, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Carcinoma, Non-Small-Cell Lung Treatment Options in Irvine, CA

If you're searching for carcinoma, non-small-cell lung treatment options in Irvine, CA, this clinical trial (NCT07586202) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Irvine research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced carcinoma, non-small-cell lung specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all carcinoma, non-small-cell lung clinical trials near you to find additional studies recruiting in your area.

More Leukemia Trials in Irvine, CA

See all leukemia clinical trials recruiting in Irvine — not just this study.

Browse Leukemia Trials in Irvine →

Browse More Trials by Condition

Leukemia TrialsSpinal Muscular Atrophy TrialsAll Conditions →

Ready to Join in Irvine?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Irvine, CA